Marys Medicine

Ndt-educational.org

Rituximab associated with mycophenolate: the LUNAR trial experience Fernando Fervenza, Rochester, USA Chairs: David Jayne, Cambridge, UK Vladimir Tesar, Prague, Czech Republic Prof. Fernando Fervenza Division of Nephrology and Hypertension Rochester, Minnesota the presentation is to discuss the results of the LUNAR trial and I have the disclosures that the trial was conducted by Genentech and Biogen. The results of the trial have already been published, almost a year ago in Arthritis Rheumatism.
The background of why LUNAR was conducted was based on the fact that rituximab, which is a chimeric CD20 antibody, has proven effective in a number of autoimmune diseases and is labelled for the treatment of rheumatoid arthritis and ANCA vasculitis. In a small number of uncontrolled trials in lupus nephritis, it has been suggested that rituximab could also be potentially effective in patients with lupus nephritis in view of the fact that we have such poor outcomes in this population and the use of rituximab may improve the outcome.
The primary objective of LUNAR was to test the efficacy and the safety of rituximab as compared to placebo when added to the background standard therapy of patients treated with prednisone and MMF.
The design of LUNAR: Briefly patients were treated with prednisone and MMF. They received 1-2 g of methyl prednisone at day 1 and they were then randomised either to continue prednisone and MMF or to receive rituximab on top of the prednisone and MMF therapy.
Patients were started on 0.75 mg of prednisone orally to a maximum of 60 mg/day. The dose was started to be tapered at day 16 and the aim was that by week-16 prednisone dose had to be 10 or less mg/kg per day. MMF was started at 500 mg 3 times/day aiming to reach a target dose of 3000 mg/day.
The inclusion criteria is briefly described here. There were patients who had a diagnosis of lupus according to the ACR criteria. They should have had a class III or class IV lupus nephritis but the coexistence of a class V lesion was allowed. Proteinuria should be more than 1 g determined by a protein/creatinine ratio. Patients who had more than 50% of glomerulosclerosis or more than 50% interstitial fibrosis as well as a creatinine clearance less than 25 ml/min or other significant involvement of lupus like retinitis, poorly controlled seizures, stroke or patients on dialysis were excluded from enrolment.
The primary endpoint of this study was a little complex as a primary endpoint and it was based on the patients who achieved a renal response. The definition of either complete, partial or non-response is represented in this slide. The complete response that is defined as a patient that at week 52 had a normalisation of serum creatinine or less than 15% greater than the baseline if the day 1 serum creatinine was indeed in the normal range. Also those patients had to have inactive urinary sediment and have a urine protein creatinine ratio of less than 0.5. The partial remission was defined by a serum creatinine of less than 15% of the baseline, above the baseline, no worsening of urinary sediment and a 50% improvement in the urine protein creatinine ratio defined as: if the baseline was less than 3, then the urine protein creatinine ratio should go down to less than 1 and if the baseline was more than 3, than the urine protein creatinine had to be less than 3. No response was achieving neither complete nor partial remission. This study was an intention-to-treat analysis so any patient was recruited was counted.
There was a number of secondary endpoints that involved a portion of patients who achieved complete remission at week 52, time to complete remission, change in the SF36 physical score and also there were some physiological measurements like the change in anti-dsDNA and change in complement levels from baseline to week 52.
The study was powered on the assumption that there would be a 20% more complete remission rate in the rituximab group versus the placebo group and there would be a 5% better number of partial remissions in the rituximab group than the partial response group.
Based on that, it was calculated that recruiting 140 patients, randomising on a one to one ratio, would give a 90% power to detect significance for this study.
This is how the patients were disposed. In fact, 144 patients were recruited, 72 patients went into the placebo arm and 72 patients in the rituximab arm. By the end of week 52, 88% of the patients in the placebo arm and 93% in the rituximab arm were still being followed as per protocol.
The baseline characteristics are summarised in this slide. It was a young patient population with an average age of about 30 years. The majority of the patients was female and race was equally divided between whites, blacks and Hispanics. One thing that is important, at least to me, is to realise that in this study 75% of the patients roughly were recruited in centres in the United States. An equal number of patients, approximately 50%, were treated at entry into the study with an ACE or an ARB.
Baseline proteinuria was around 4 g. Serum creatinine was normal and this was reflected by an eGFR of close to 90 ml/min. Regarding the renal biopsy, the majority of the patients had a class IV lupus nephritis, a third of the patients had class III lupus nephritis and a third of the patients also had a class V lupus lesion associated.
Here are the main results of the study. Basically, to cut a long story short, there was no difference in the rate of complete remission in patients treated with placebo or rituximab.
There was a 15% increase or a doubling of the number of patients reaching partial remission but this was not significant. One of the most concerning results was that approximately 50% of the patients enrolled in LUNAR and treated in centres where perhaps people believe they know how to treat this disease could not reach even a partial remission of nephritis.
When you look at the renal response at 52 weeks and using the combined complete plus partial remission, there was a tendency for rituximab to be of greater benefit than the placebo group although this did not reach statistical significance.
The improvement of the renal response was gradual and progressive up to 52 weeks but when we looked at the response or the proteinuria in the group, there was no difference although this slide does not show you the patients that were markers of autoimmunity like anti-dsDNA, complement levels responded better also had better response with regards to reduction of proteinuria.
Regarding the secondary endpoints, the main differences were in fact in the serological biomarkers where patients treated with rituximab had a better response in lowering anti- dsDNA levels and a better response on increasing C3 and C4 complement levels.
Regarding the steroid dose, there was no significant difference in the cumulative dose in the patients of the placebo group versus the group that received rituximab. However, there was a tendency that at the end of this study, of less steroid use in the rituximab arm.
When the study was re-divided to evaluate race, there was a tendency for African- Americans to respond better to rituximab than to placebo but there was no difference between Hispanics or Caucasians and the better response in the African-American contingence was basically due to the higher degree of partial remission in this patient population.
Regarding safety one good signal was that adding rituximab to a background of prednisone or CellCept did not increase the number of serious adverse events or infectious complications or other adverse events. Interestingly, the presence of human anti-chimeric antibodies that are antibodies produced against a foreign toxin like rituximab for example, were present in 11% of patients with rituximab but even patients with placebo also developed anti-chimeric Regarding death there were two deaths and both occurred in the rituximab arm. One of a patient of sepsis on day 64 and one of a patient with pneumocystis pneumonia at day 58.
This tells us how important it is to do prophylaxis on patients with rituximab again with pneumocystis pneumonia because B cells are essential to keep pneumocystis at bay.
The conclusions of the LUNAR are the following. To date LUNAR is the largest randomised placebo controlled trial to evaluate an intervention in lupus nephritis. Although there were numerically more responders in the rituximab group, 57 versus 46, the study did not show a statistically significant difference in the primary or clinical secondary endpoints at week 52.
Rituximab had a significant effect on the level of anti-dsDNA and complement at week 52, although the clinical significance of this is unclear. Adverse events and serious adverse events were similar in frequency between the groups with no new or unexpected safety signals.
So the question is, what went wrong with LUNAR? This is something that doctor Liz Livingstone wrote very eloquently in an editorial that accompanied the results of LUNAR.
I would like to bring to the appointment that maybe part of the issues come in the assumption of the sample size determination. LUNAR was very tough in the fact that they were very optimistic in trying to get a rate of complete response in lupus nephritis of 50%.
Now anyone who deals with lupus nephritis knows that that is probably a little bit too far because no study to my understanding has reached 50% complete remission ever and to underestimate the reason of partial remission. I'd like to remind you that in fact, the LUNAR found a 15% advantage of partial remission in the patients treated with rituximab versus placebo. I remind you that a delta of 15% in the endpoint but then including 2133 patients led the FDA to approve Belimumab in a non-renal lupus study based on much less stronger criteria of proteinuria rather than some questionnaires that are of doubtful significance.
Another issue is that we have to remember that the use of rituximab was associated not only with a significant increase in C3 and C4 complement levels but also in anti-dsDNA levels.
Using another disease but just as an example, this is a study that we conducted in patients with membranous nephropathy treated with rituximab. When you look at the anti-PLA2R that is a marker theoretically of disease activity. You can see that by the 12 months there is a significant decrease of the levels of the antibody. But still, despite almost disappearance of all the antibodies in all patients, you still can see that the proteinuria still remains quite In fact, doctor Remuzzi's group showed in a recent paper again in the patients with membranous nephropathy treated with rituximab that it takes at least 2-3 years for proteinuria to reach its -. So one of the problems with LUNAR I think and in any study that uses proteinuria as you endpoint is that 12 months in my view is not enough for you to see the total effect.
Lastly there is a perception that just because you want to treat someone that the kidney is going to behave as you expect it to. This is a kidney biopsy in a patient again with membranous nephropathy before and after treatment with rituximab and you can see that in this second biopsy done two years later, all the subepithelial deposits present here have completely disappeared but the glomerular basement membrane is markedly distorted. As such, is not a surprise that proteinuria persista ta abiout 1 g/24h but his anti-PLA2R levels that were high to begin with had become undetectable for the last 12 months. Thus the patient had reached immunological remission but proteinuria persist because of damage to the GBM. So we could argue that to use proteinuria as a definition of remission is complete ignorance of the immunological situation. Therefore, and I think Doctor Ferrario is going to talk about the importance of re-biopsying those patients because we are at the moment trying to design therapies mainly just looking with one eye =proteinuria. I would argue that re- biopsying these patients and taking into consideration the results of the biopsy together with immunological results are the way to go into future studies of lupus nephritis. In addition, a longer follow-up is really needed to assess those results.
Thank you very much.

Source: http://www.ndt-educational.org/dati/pagine/allegato_201405101232.pdf

127368 oxford nutrascience admission doc pt

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubtabout the contents of this document you should consult your stockbroker, bank manager, solicitor, accountant or otherindependent professional adviser authorised for the purposes of the FSMA, who specialises in advising on theacquisition of shares and other securities. An investment in the Company involves a significant degree of risk and maynot be suitable for all recipients of this document. Investors should consider carefully the "Risk Factors" which are setout in Part III of this document.

Isep 2005 post meeting

International Symposium for Ectoparasites of Pets. May 2005 in Hannover 8th ISEP Program Committee Senior Project Leader PR Pharmaceuticals, Inc 1716 Heath Parkway Fort Collins CO 80524 p 970 494 2342 f 970 482 6184 adonoghue@prpharm.com Hannover University of Veterinary Medicine Department for Infectious Diseases Institute for Parasitology Buenteweg 17; D-30559 Hannover Tel/Phone: +49 511 953 8797; Fax: +49 511 953 8583 Christian.Epe@tiho-hannover.de